Mark A. Till
Impact in
- Biotechnology top 1%
- Transgenic Plants and Applications
- Microbial Inactivation Methods
- Immunology top 5%
- Toxin Mechanisms and Immunotoxins
- Immune Cell Function and Interaction
Papers in
-
- Transgenic Plants and Applications 8
- Immunology 11
- Toxin Mechanisms and Immunotoxins 10
- Galectins and Cancer Biology 3
- Immunotherapy and Immune Responses 1
- Co-authors
- Richard D. May (8 shared papers)Ellen S. Vitetta (7 shared papers)Jonathan W. Uhr (6 shared papers)R J Fulton (2 shared papers)Victor F. Ghetie (7 shared papers)Peter L Amlot (3 shared papers)J W Uhr (5 shared papers)Robert H. Collins (1 shared paper)
- Journals
- Science (2 papers)International Journal of Cancer (1 paper)Cellular Immunology (1 paper)Bioconjugate Chemistry (1 paper)Proceedings of the National Academy of Sciences (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Mark A. Till
12 papers receiving 956 citations
Peers
Comparison fields: 5 of 67
- Biotechnology 475
- Immunology 781
- Virology 90
- Radiology, Nuclear Medicine and Imaging 386
- Toxicology 18
Countries citing papers authored by Mark A. Till
This map shows the geographic impact of Mark A. Till's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Till with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Till more than expected).
Fields of papers citing papers by Mark A. Till
This network shows the impact of papers produced by Mark A. Till. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Till. The network helps show where Mark A. Till may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Till, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1987 | 299 | |
| 2 | Phase I immunotoxin trial in patients with B-cell lymphoma. | 1991 | 256 |
| 3 | 1988 | 129 | |
| 4 | Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. | 1988 | 114 |
| 5 | 1988 | 68 | |
| 6 | 1989 | 57 | |
| 7 | An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. | 1988 | 42 |
| 8 | 1989 | 33 | |
| 9 | 1990 | 22 | |
| 10 | Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. | 1990 | 18 |
| 11 | 1990 | 12 | |
| 12 | Monoclonal antibodies as carriers of toxins. | 1989 | 3 |
About Mark A. Till
Mark A. Till is a scholar working on Biotechnology, Immunology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Neurology, having authored 12 papers that have together received 1.1k indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (10 papers), Transgenic Plants and Applications (8 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Galectins and Cancer Biology (3 papers), Glycosylation and Glycoproteins Research (2 papers), Plant tissue culture and regeneration (2 papers), Herpesvirus Infections and Treatments (1 paper) and Immunotherapy and Immune Responses (1 paper). The work is most often cited by research in Biotechnology (475 citations), Immunology (781 citations), Virology (90 citations), Radiology, Nuclear Medicine and Imaging (386 citations) and Toxicology (18 citations). Mark A. Till has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Richard D. May, Ellen S. Vitetta, Jonathan W. Uhr, R J Fulton, Victor F. Ghetie, Peter L Amlot, J W Uhr, Robert H. Collins, Marvin J. Stone and David Cunningham. Their work appears in journals such as Science, International Journal of Cancer, Cellular Immunology, Bioconjugate Chemistry and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.